The world of biologicals continues to rapidly evolve, whilst diversifying in terms of therapeutic targets, available molecules, and indications. Notably, the way to manage severe atopic dermatitis will substantially change in 2018 following the introduction of dupilumab, an anti-IL-4 and IL-13, with considerable efficacy in Phase III clinical studies. In addition, rituximab was demonstrated to be associated with clinical remission in many patients with pemphigus.
In oncology, and especially in melanoma staging, the 8th edition of the American joint committee on cancer (AJCC) classification edition produced a revision of T1a definition, with Breslow thickness presently being ≤0.8mm versus 1mm in the previous classifications. In allergology, glucose sensors made headlines, given that many cases of contact allergy have been reported following their introduction. The likely allergen involved is an acrylate present in the adhesive part of the electrode
psoriasis, atopic dermatitis, contact eczema, glucose sensors, DRESS, IL-4, IL-13, IL-17, melanoma